Summary
Deoxyspergualin, the 15-deoxy derivative of the antibiotic spergualin, is a novel guanidino analog structurally related to spermine. Deoxyspergualin has significant activity in selected experimental tumor models, and clinical trials have been initiated. Described here are in vivo evaluations of the therapeutic activity of deoxyspergualin against murine leukemia lines specifically resistant to eight clinically useful antitumor drugs. These were P388 lines resistant to doxorubicin, vincristine, L-phenylalanine mustard, cisplatin, ara-C, and methotrexate and L1210 lines resistant to 5-FU, L-phenylalanine mustard, and cyclophosphamide. Sensitivity to deoxyspergualin was evaluated in parallel comparisons of each resistant leukemia to the sensitive line from which it had been derived. All experiments were repeated at least once for confirmation of results. Responses were quantitated in terms of the change in tumor cell numbers from the beginning of treatment to the end of treatment as estimated from the median survival times of dying mice. The results indicated that P388 leukemia resistant to cisplatin (P388/DDPt) was cross-resistant to deoxyspergualin. No cross-resistance was observed in leukemias resistant to doxorubicin, vincristine, ara-C, methotrexate, or cyclophosphamide. L1210 resistant to 5-FU (L1210/5-FU) was collaterally sensitive to deoxyspergualin. Although cross-resistance was also observed in P388/L-PAM, L1210/L-PAM retained sensitivity to deoxyspergualin. Total glutathione concentrations in P388/L-PAM and L1210/L-PAM provided no apparent explanation for this unexpected result. It may be tentatively concluded that resistance to cisplatin, L-PAM, or other DNA alkylators or cross-linkers may increase the potential for cross-resistance to deoxyspergualin. This conclusion requires verification with additional alkylating agents, with drug-resistant human tumor cell lines, and with prospective clinical studies. However, it has present implications for the mechanism(s) of deoxyspergualin activity, for the selection of patients for clinical trials of this investigational new drug, and for the design of noncross-resistant drug combinations.
Similar content being viewed by others
References
Estey E, Hoth D, Simon R, Marsoni S, Leyland-Jones B, Wittes R: Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep 70:1105–1115, 1986
Schabel Jr FM, Skipper HE, Trader MW, Laster Jr WR, Griswold Jr DP, Corbett TH: Establishment of cross- resistance profiles for new agents. Cancer Treat Rep 68:453–459, 1984
Iwasawa H, Kondo S, Ikeda D, Takeuchi T, Umezawa H: Synthesis of (-)-15-deoxyspergualin and (-)-spergualin-15-phosphate. J Antibiot 35:1665–1669, 1982
Harrison Jr SD, Dykes DJ, Plowman J, Griswold Jr DP: Evaluation of deoxyspergualin infusions against L1210 leukemia. (Abstract) Proc Am Assoc Cancer Res 27:277, 1986
Plowman J, Harrison Jr SD, Trader MW, Griswold Jr DP, Chadwick M, McComish MF, Silveira DM, Zaharko D: Preclinical antitumor activity and pharmacological properties of deoxyspergualin. Cancer Res 47:685–689, 1987
McComish MF, Silveira DM, Hogan EJ, Branfman AR, Chadwick M: Assay development and preclinical pharmacology of deoxyspergualin (NSC 356894). Proc Am Assoc Cancer Res (Abstr) 27:407, 1986
Eltman RH, Boysen BG, Basel DL, Glaza SM, Dickie BC, Kastello MD, Grieshaber CK: The toxicologic evaluation of 15-deoxyspergualin HC1 (NSC 356894) in CD2F1 mice, Fischer 344 rats, and beagle dogs. Proc Am Assoc Cancer Res (Abstr) 27:418, 1986
Boysen BG, Weltman RH, Basel DL, Dickie BC, Kastello MD, Grieshaber CK: The toxicologic evaluation of 15-deoxyspergualin HC1 (NSC 356894) after continuous in- travenous infusion in beagle dogs. Proc Am Assoc Cancer Res (Abstr) 27:418, 1986
Schabel Jr FM, Griswold Jr DP, Laster Jr WR, Corbett TH, Lloyd HH: Quantitative evaluation of anticancer agent activity in experimental animals. Pharmac Ther 1:411–435, 1977
Lloyd HH: Application of tumor models toward the design of treatment schedules for cancer chemotherapy. In: Drewinko B, Humphrey RM (eds) Growth Kinetics and Biochemical Regulation of Normal and Malignant Cells. Williams & Wilkins Co, Baltimore, 1977, pp 455–469
Griffith OW: Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 106:207–212, 1980
Suzukake K, Petro BJ, Vistica DT: Reduction in glutathione content of L-PAM resistant L1210 cells confers drug sensitivity. Biochem Pharmac 31:121–124, 1982
Burchenal JH: Some problems basic to cancer research with particular reference to chemotherapy. Cancer Res 23:1186–1190, 1963
Brockman RW, Wheeler GP: Biological and biochemical characterization of deoxyspergualin (NSC 356894), a polyamine antitumor antibiotic. Proc Am Assoc Cancer Res (Abstr) 26:255, 1985
Wheeler GP: Studies related to mechanisms of resistance to biological alkylating agents. Cancer Res 23:1334–1349, 1963
Hilton J: Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res 44:5156–5160, 1984
Sladek NE, Smith PC, Bratt PM, Low JE, Powers JF, Borch RF, Coveney JR: Influence of diuretics on urinary general base catalytic activity and cyclophosphamide-induced bladder toxicity. Cancer Treat Rep 66:1889–1900, 1982
Ozols RF, Cowan K: New aspects of clinical drug resistance: the role of gene amplification and the reversal of resistance in drug refractory cancer. In: DeVita Jr VT, Hellman S, Rosenberg SA (eds) Important Advances in Oncology 1986. JB Lippincott, Philadelphia, 1986, pp 129–157
Tabor H, Tabor CW: Isolation, characterization, and turnover of glutathionylspermidine from Escherichia coli. J Biol Chem 250: 2648–2654, 1975
Author information
Authors and Affiliations
Additional information
Mrs. Mary W. Trader died on January 16, 1987, while this manuscript was in preparation.
Rights and permissions
About this article
Cite this article
Harrison, S.D., Brockman, R.W., Trader, M.W. et al. Cross-resistance of drug-resistant murine leukemias to deoxyspergualin (NSC 356894) in vivo . Invest New Drugs 5, 345–351 (1987). https://doi.org/10.1007/BF00169973
Issue Date:
DOI: https://doi.org/10.1007/BF00169973